drugset
drugset / Trial / NCT03012165

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03012165 ↗

Phase 2 Completed 154 enrolled Aldeyra Therapeutics, Inc. ORA, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

Timeline

Start
2016-12
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.1 % Other
Subject Reproxalap Other / unclassified 0.5 % Other

Indications

conjunctivitis